Advertisement

Topics

Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

15:18 EST 13 Nov 2017 | BioPortfolio Reports

Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 Pipeline Review, H2 2017


Summary


Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 Lymphocyteactivation gene 3 or LAG3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA classII antigens.


Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 8 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, NonSmall Cell Lung Cancer, Advanced Malignancy, Autoimmune Disorders, Lymphoma, Melanoma, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Kidney Cancer Renal Cell Cancer, NonHodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis Psoriasis Vulgaris, Recurrent Glioblastoma Multiforme GBM, Refractory Chronic Lymphocytic Leukemia CLL, Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia CLL, Relapsed Multiple Myeloma and Renal Cell Carcinoma.


The latest report Lymphocyte Activation Gene 3 Protein Pipeline Review, H2 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3

The report reviews Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics and enlists all their major and minor projects

The report assesses Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Lymphocyte Activation Gene 3 Protein Protein FDC or CD223 or LAG3 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...